Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Vyndamax
Pharma
Pfizer to discontinue low-dose ATTR drug Vyndaqel in US in 2025
Pfizer is pulling the trigger on the full transition to Vyndamax as Vyndaqel is expected to lose patent protection in 2028.
Angus Liu
Aug 29, 2025 10:40am
Alnylam's market cap jumps past $50B
Aug 1, 2025 7:39am
Look out, Pfizer: BridgeBio gains 'best-case' FDA nod for Attruby
Nov 25, 2024 7:59am
Pfizer's ATTR drug again faces pricing scrutiny
Oct 21, 2024 2:55pm
Pfizer's ATTR drug needs hefty discount, says ICER draft report
Jul 18, 2024 4:37pm
Alnylam touts 'big-win scenario' for closely watched heart trial
Jun 24, 2024 10:53am
